Fundacio Privada Cemcat
- Address
- Edif. Cemcat, Passeig De La Vall D'Hebron 119, 08035 Barcelona, Spain
Fundacio Privada Cemcat - Multiple Sclerosis Research
Fundacio Privada Cemcat is a specialized clinical research center dedicated to advancing treatment options for neurological disorders, with particular expertise in multiple sclerosis therapeutics. The center conducts innovative comparative effectiveness trials to evaluate emerging therapies against established treatment standards.
- Relapsing multiple sclerosis treatment evaluation
- Novel immunomodulatory therapy research
- Long-term safety and efficacy assessments
The center's research portfolio emphasizes rigorous clinical investigation of disease-modifying therapies designed to reduce relapse frequency and progression in MS patients. Through carefully designed superiority trials, Fundacio Privada Cemcat contributes valuable evidence to help clinicians optimize treatment selection and improve outcomes for individuals living with relapsing forms of multiple sclerosis.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Fundacio Privada Cemcat
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Double-Blind Study Comparing Remibrutinib and Teriflunomide in Relapsing Multiple Sclerosis Patients, with Open-Label Remibrutinib Extension | Novartis Pharma AG | Phase III | Not Recruiting | Jun 2022 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Charcoal, Activated | 1 | Unknown | 2022-06-22 | 2022-06-22 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.